tiprankstipranks
Analyst Profile
Followed by 60 other investors
.
Yatin Suneja

Yatin Suneja

Guggenheim
Wall Street Analyst
Ranked #6,980 out of 8,047 Analysts on TipRanks (#18,641 out of 21,521 overall experts)

Success Rate

40%
59 out of 149 Profitable Transactions

Average Return

-3.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Yatin Suneja's ratings since 2014 and opened each position for the duration of 1 Year:
39.60% of your transactions would have been profitable with an average return of -3.2%

Stock Rating Distribution

223Ratings
72.65% Buy
27.35% Hold
0.00% Sell
Distribution of Yatin Suneja's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Axsome Therapeutics Inc.
(AXSM)
Rating Type:Buy
Dates:Oct 16, 2019 - Oct 16, 2020
Gain:240.90%
The most profitable rating made by Yatin Suneja

Yatin Suneja's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Omeros
Buy
Reiterated
0%
-3.30%
1
Sierra Oncology
Hold
Reiterated
0.00%
2
Ariad
Hold
Downgraded
50%
+35.30%
3
Verona Pharma
Buy
Initiated
$26.00
(91.32% Upside)
100%
+4.00%
1
IVERIC bio
Hold
Reiterated
$3.00
(-77.74% Downside)
0%
-1.10%
5
TG Therapeutics
Buy
Assigned
80%
+20.86%
6
GlycoMimetics
Buy
Reiterated
$32.00
(3537.60% Upside)
75%
+39.10%
4
MEI Pharma
Buy
Initiated
$12.00
(2105.88% Upside)
0%
-51.10%
1
Agios Pharma
Buy
Reiterated
$123.00
(336.94% Upside)
71%
+9.80%
7
Seagen
Buy
Reiterated
$81.00
(-52.39% Downside)
50%
+0.90%
9
List of latest recommendations made by Yatin Suneja. Click to expand and see Yatin Suneja's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More